The immunogenicity of midbrain dopaminergic neurons and the implications for neural grafting trials in Parkinson's disease.
Howlett, Sarah K
Jones, Joanne L
Barker, Roger A
MetadataShow full item record
Qarin, S., Howlett, S. K., Jones, J. L., & Barker, R. A. (2021). The immunogenicity of midbrain dopaminergic neurons and the implications for neural grafting trials in Parkinson's disease.. Neuronal signaling, 5 (3) https://doi.org/10.1042/ns20200083
Dopaminergic (DA) cell replacement therapies are a promising experimental treatment for Parkinson's disease (PD) and a number of different types of DA cell-based therapies have already been trialled in patients. To date, the most successful have been allotransplants of foetal ventral midbrain but even then, the results have been inconsistent. This coupled to the ethical and logistical problems with using this tissue has meant that an alternative cell source has been sought of which human pluripotent stem cells (hPSCs) sources have proven very attractive. Robust protocols for making mesencephalic DA (mesDA) progenitor cells from hPSCs now exist and the first in-human clinical trials have or are about to start. However, while their safety and efficacy are well understood, relatively little is known about their immunogenicity and in this review, we briefly summarise this with reference mainly to the limited literature on human foetal DA cells.
Immunogenicity, Transplant, Immune rejection, Parkinson’s Disease, Dopaminergic, Human Foetal Ventral Midbrain
Wellcome Trust (203151/Z/16/Z)
External DOI: https://doi.org/10.1042/ns20200083
This record's URL: https://www.repository.cam.ac.uk/handle/1810/329837
Attribution 4.0 International
Licence URL: https://creativecommons.org/licenses/by/4.0/
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: firstname.lastname@example.org